Ceride Therapeutics Co., Ltd. selected for NEDO’s Deep Tech Startup Support Project (DTSU)
*View in browser* *Celeide Therapeutics Co., Ltd.*
Press release: March 22, 2024
**
Ceride Therapeutics Co., Ltd. selected for NEDO’s Deep Tech Startup Support Project (DTSU)
Ceride Therapeutics Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, Representative Director: Nobuyuki Arakawa, hereinafter referred to as the “Company”) is a member of the New Energy and Industrial Technology Development Organization, a national research and development corporation.
3rd public call for 2023 “Deep Tech Startup Support Project
(hereinafter referred to as “DTSU”) conducted by (NEDO)
We would like to inform you that we have been selected for the STS phase (practical research and development (first half)) with the University of Tokyo Edge Capital Partners (UTEC) as our partner VC. With this selection, we aim to quickly implement human hematopoietic stem cell expansion technology in society in order to save patients suffering from blood and genetic diseases around the world.
* Selected project name: Development of human hematopoietic stem cell expansion platform technology for gene therapy and cell therapy products *
Business overview: Establishment and application demonstration of clinical/commercial grade human hematopoietic stem cell expansion methods and culture medium supply systems in order to solve technical issues in commercial manufacturing of gene therapy and cell therapy products developed by bioventures and global pharmaceutical companies. do an experiment.
Since its founding in October 2020, Cereid Therapeutics Co., Ltd. has been working on research and development of in vitro amplification technology for human hematopoietic stem cells, and at the same time has set its sights on the global market, including the US market, from an early stage.
, we have participated in various global accelerator programs and American university communities to develop our business (Reference 1) ). During this process, we discovered that our human hematopoietic stem cell expansion technology could solve the technical challenges faced by companies developing gene therapy and cell therapy products in Japan and overseas. Having been selected for this NEDO project, we aim to upgrade our basic technology for clinical and commercial manufacturing and build a foundation for companies around the world to use our human hematopoietic stem cell expansion technology.
* About Ceride Therapeutics Co., Ltd. *
Ceraid Therapeutics is a startup from the University of Tokyo and the University of Tsukuba that has unique technology to selectively amplify hematopoietic stem cells, which are the source of human blood, in vitro. By safely and efficiently increasing hematopoietic stem cells, we can provide cell therapy for intractable blood diseases and genetic diseases, including blood cancers.*
We are aiming for social implementation in ex vivo* hematopoietic stem cell gene therapy, etc.
-Contact information regarding this matter-
*Celeide Therapeutics Co., Ltd.*
Head office location: Entrepreneur Lab, South Research Building, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo
TEL: 050-3612-7767／E-mail: contact@celaidtx.com
URL: https://celaidtx.com/
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000007.000100408.html
*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=100408&release_id=7